These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 25193435

  • 1. Early evaluation of the therapeutic effect of denosumab on tartrate-resistant acid phosphatase 5b expression in a giant cell tumor of bone: a case report.
    Watanabe N, Matsumoto S, Shimoji T, Ae K, Tanizawa T, Gokita T, Motoi N, Ueno T, Koizumi M.
    BMC Res Notes; 2014 Sep 05; 7():608. PubMed ID: 25193435
    [Abstract] [Full Text] [Related]

  • 2. Denosumab: a new treatment option for giant cell tumor of bone.
    Lewin J, Thomas D.
    Drugs Today (Barc); 2013 Nov 05; 49(11):693-700. PubMed ID: 24308016
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of Patients with Giant Cell Tumor of Bone and High Serum Tartrate-Resistant Acid Phosphatase 5b Levels: Comparison of Tumor Volume and Clinical Factors.
    Hayashida K, Kawabata Y, Yoshida T, Saito K, Fujita S, Choe H, Kato I, Takeyama M, Inaba Y.
    J Nippon Med Sch; 2022 Nov 05; 89(6):572-579. PubMed ID: 36725001
    [Abstract] [Full Text] [Related]

  • 4. RANKL, denosumab, and giant cell tumor of bone.
    Thomas DM.
    Curr Opin Oncol; 2012 Jul 05; 24(4):397-403. PubMed ID: 22581354
    [Abstract] [Full Text] [Related]

  • 5. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.
    Clin Cancer Res; 2012 Aug 15; 18(16):4415-24. PubMed ID: 22711702
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
    Mose S, Menzel C, Kurth AA, Obert K, Ramm U, Eberlein K, Boettcher HD, Pichlmeier U.
    Anticancer Res; 2005 Aug 15; 25(6C):4639-45. PubMed ID: 16334155
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Denosumab: Current Use in the Treatment of Primary Bone Tumors.
    Savvidou OD, Bolia IK, Chloros GD, Papanastasiou J, Koutsouradis P, Papagelopoulos PJ.
    Orthopedics; 2017 Jul 01; 40(4):204-210. PubMed ID: 28732103
    [Abstract] [Full Text] [Related]

  • 12. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.
    Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL.
    Clin Orthop Relat Res; 2015 Sep 01; 473(9):3050-5. PubMed ID: 25758379
    [Abstract] [Full Text] [Related]

  • 13. The clinical approach toward giant cell tumor of bone.
    van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovée JV, Hogendoorn PC, Gelderblom H.
    Oncologist; 2014 May 01; 19(5):550-61. PubMed ID: 24718514
    [Abstract] [Full Text] [Related]

  • 14. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.
    Matcuk GR, Patel DB, Schein AJ, White EA, Menendez LR.
    Skeletal Radiol; 2015 Jul 01; 44(7):1027-31. PubMed ID: 25712768
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
    Deveci MA, Paydaş S, Gönlüşen G, Özkan C, Biçer ÖS, Tekin M.
    Acta Orthop Traumatol Turc; 2017 Jan 01; 51(1):1-6. PubMed ID: 27784623
    [Abstract] [Full Text] [Related]

  • 18. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review.
    Bardakhchyan S, Kager L, Danielyan S, Avagyan A, Karamyan N, Vardevanyan H, Mkhitaryan S, Papyan R, Zohrabyan D, Safaryan L, Sargsyan L, Harutyunyan L, Hakobyan L, Iskanyan S, Tamamyan G.
    Ital J Pediatr; 2017 Mar 29; 43(1):32. PubMed ID: 28356124
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab.
    Chandler A, Bartelstein MK, Fujiwara T, Antonescu CR, Healey JH, Vaynrub M.
    BMC Musculoskelet Disord; 2021 Apr 01; 22(1):320. PubMed ID: 33794838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.